New treatment strategy with bone marrow-derived mesenchymal stem cells for obstructive nephropathy

骨髓间充质干细胞治疗梗阻性肾病的新策略

• 批准号: 23592377
• 负责人: ASANUMA Hiroshi
• 金额: $ 3.33万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23592377/
• 关键词: 間葉系幹細胞; 上皮・間葉系形質転換; 腎線維化; 増殖因子; サイトカイン; 閉塞性腎症; 再生医学; 細胞療法

The effect of mesenchymal stem cells (MSCs) therapy on chronic obstruction-induced renal fibrosis has not previously been evaluated. Rats with left ureteral obstruction underwent injection of fluorescent-labeled human and rat bone marrow-derived MSCs. From 3 days to 4 weeks later, the kidneys were harvested and the renal cortex analyzed for evidence of stem cell infiltration, epithelial-mesenchymal transition (EMT), renal fibrosis, and cytokine and growth factor activity.MSCs were detected in the interstitium of the kidney more than 4 weeks post-obstruction. MSCs provided protection against obstruction-induced EMT and chronic renal fibrosis. While the mechanism of MSCs-induced renal protection during obstruction remains unclear, exogenous MSCs reduced obstruction-induced TNF-alpha levels, but did not alter TGF-beta1, VEGF, IL-10, FGF, HGF expression.

以前尚未评估间充质干细胞（MSC）治疗对慢性阻塞引起的肾纤维化的影响。左输尿管阻塞的大鼠接受了荧光标记的人和大鼠骨髓来源的MSC的注射。从3天到4周后，收集了肾脏，并分析了肾皮质，以证明干细胞浸润，上皮 - 间质转变（EMT），肾纤维化和细胞因子和生长因子活性。MSC在肾脏后4周的肾小管室内检测到了MSC。 MSC提供了防止阻塞引起的EMT和慢性肾纤维化的保护。尽管在阻塞过程中，MSC诱导的肾脏保护的机制尚不清楚，但外源MSC降低了阻塞诱导的TNF-Alpha水平，但并未改变TGF-BETA1，VEGF，IL-10，IL-10，FGF，HGF，HGF表达。

项目成果

閉塞性腎症に対する骨髄由来間葉系幹細胞注入療法の有効性

骨髓间充质干细胞注射治疗梗阻性肾病的疗效

• 发表时间: 2014
• 作者: Fujii Y;Okada A;Yasui T;Niimi K,Hamamoto S;Hirose M;Kubota Y;Tozawa K;Hayashi Y;Kohri K.;浅沼宏
• 通讯作者: 浅沼宏

閉塞性腎症のよる尿細管間質障害

梗阻性肾病引起的肾小管间质疾病

• 发表时间: 2011
• 期刊: 腎と透析
• 作者: 浅沼宏;大家基嗣
• 通讯作者: 大家基嗣